OT3-01-17: Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Low-Dose Metronomic Cyclophosphamide Alone or in Combination with Veliparib (ABT-888) in Chemotherapy-Resistant ER and/or PR-Positive, HER2/neu-Negative Metastatic Breast Cancer: New York Cancer Consortium Trial P8853.
E Andreopoulou
◽
AP Chen
◽
JA Zujewski
◽
K Kalinsky
◽
L Vahdat
◽
...